STRIDE™ in DNA Damage Analysis (CEO & Co-Founder gives intro to the STRIDE™ platform)

M. Kordon-Kiszala

STRIDE™ as a technology platform for accurate measurement of DNA breaks and breaks-associated repair proteins (AACR Synthetic Lethality Special Conference 2024)

A. Uherek, K. Stępień, O. Wójcikowska, K. Solarczyk, et al.

LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency

A. Kulkarni, J. Zhou, Z. Prucsi, K. Solarczyk, et al.

Novel dSTRIDE-HR assays can accurately assess DNA repair defects in human cancers and distinguish HR status of tumors (AACR 2024)

M. Jarosz, Z. Prucsi, F. Sierpowski, K. Solarczyk, et al.

Measuring the activity of SMUG1 DNA glycosylase with a novel sSTRIDE-SMUG1 assay (AACR 2024)

K. Stępień, F. Sierpowski, Z. Prucsi, K. Solarczyk, et al.

Studying the MoA of the next generation chemotherapeutic LP-284, a small molecule acylfulvene in a chronic myelogenous leukemia cell line model using STRIDE™

Studying the effects of alpha and beta-emitters alone and in combination with a DDR inhibitor in a human cell line model

Studying the MoA of a DDR inhibitor in Patient-Derived Xenograft (PDX) models using STRIDE

Detection of DNA damage using STRIDE as a new PD biomarker in liquid biopsies and FFPE tissue sections

K. Solarczyk, A. Waligórska, M. Szczygieł, P. Waring, G. Jones, et al.

Why gammaH2AX is not enough? (DDR Inhibitors Summit 2024)

M. Kordon-Kiszala

Development and validation of a customized, functional STRIDE-based assay to measure Mismatch Repair (MMR) pathway activity in cells

sSTRIDE as a technology platform for the detection and measurement of DNA breaks in various DNA repair pathways (DDR Inhibitors Summit 2024)

M. Białecka, K. Uznańska, O. Wójcikowska, K. Solarczyk, et al.

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin’s lymphoma models and in cells deficient in DNA damage repair

J. Zhou, D. Sturtevant, C. Love, A. Kulkarni, K. Bhatia, et al.

Development and validation of a novel sSTRIDE-MMR functional assay to study the efficiency of MMR inhibitors (AACR 2023)

M. Białecka, K. Solarczyk, K. Uznańska, O. Wójcikowska, et al.

Novel functional dSTRIDE-HR assays to report on the status of homologous recombination repair in cancer cells (AACR 2023)

K. Solarczyk, A. Waligórska, K. Uznańska, Z. Prucsi, et al.

Let’s not take DNA breaks for granted. The importance of direct detection of DNA breaks for the successful development of DDR inhibitors

M. Kordon-Kiszala and K. Solarczyk

Ubiquitinated PCNA drives USP1 synthetic lethality in cancer

A. Simoneau, J. Engel, M. Bandi, K. Lazarides, S. Liu, et al.

Breakage of CRISPR/Cas9-Induced Chromosome Bridges in Mitotic Cells

M. Rodriguez-Muñoz, M. Serrat, D. Soler, A. Genescà and T. Anglada

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

J. Gozgit, M. Vasbinder, R. Abo, K. Kunii, K. Kuplast-Barr, et al.

STRIDE—a fluorescence method for direct, specific in situ detection of individual single- or double-strand DNA breaks in fixed cells

M. Kordon-Kiszala, M. Zarębski, K. Solarczyk, H. Ma, T. Pederson, J. Dobrucki